NASDAQ:LTRN Lantern Pharma (LTRN) Stock Forecast, Price & News $3.28 -0.13 (-3.81%) (As of 02:34 PM ET) Add Compare Share Share Today's Range$3.25▼$3.4350-Day Range$3.41▼$5.0052-Week Range$3.25▼$6.20Volume14,973 shsAverage Volume34,365 shsMarket Capitalization$35.65 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lantern Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside236.4% Upside$11.00 Price TargetShort InterestHealthy2.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.75) to ($2.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector752nd out of 969 stocksPharmaceutical Preparations Industry363rd out of 453 stocks 3.3 Analyst's Opinion Consensus RatingLantern Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Lantern Pharma has a forecasted upside of 236.4% from its current price of $3.27.Amount of Analyst CoverageLantern Pharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.09% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 3.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LTRN. Previous Next 2.7 News and Social Media Coverage News SentimentLantern Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lantern Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.92% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 10.61% of the stock of Lantern Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lantern Pharma are expected to decrease in the coming year, from ($1.75) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantern Pharma (NASDAQ:LTRN) StockLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More LTRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LTRN Stock News HeadlinesSeptember 28, 2023 | marketbeat.com8 Best Artificial Intelligence Stocks Under $10 (LTRN)If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more.September 29, 2023 | finance.yahoo.comLTRN: Spotlight on LP-184 & 284October 2, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 25, 2023 | finance.yahoo.comLantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsSeptember 18, 2023 | finance.yahoo.comLantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s LymphomasSeptember 5, 2023 | msn.comLantern Pharma (LTRN) Price Target Increased by 18.27% to 20.91August 31, 2023 | finance.yahoo.comLantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual MeetingAugust 14, 2023 | finance.yahoo.comLantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRTOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 10, 2023 | finance.yahoo.comLTRN: 2Q:23 Quarterly UpdateAugust 10, 2023 | markets.businessinsider.comLantern Pharma (LTRN) Receives a Hold from H.C. WainwrightAugust 9, 2023 | finance.yahoo.comLantern Pharma Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 2, 2023 | finance.yahoo.comLantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ETJuly 17, 2023 | finance.yahoo.comLantern Pharma to Participate and Present at Multiple Upcoming ConferencesJune 27, 2023 | msn.comEF Hutton Maintains Lantern Pharma (LTRN) Buy RecommendationJune 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Lantern Pharma (LTRN)June 26, 2023 | finance.yahoo.comOncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s LymphomasJune 12, 2023 | msn.comLantern Pharma gets FDA clearance to begin P1 testing for LP-184June 12, 2023 | finance.yahoo.comLantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid TumorsJune 8, 2023 | finance.yahoo.comLantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld UniversityMay 28, 2023 | hk.finance.yahoo.comLTRN - Lantern Pharma Inc.May 18, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Lantern Pharma (LTRN) with Neutral RecommendationMay 17, 2023 | finance.yahoo.comLantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ETMay 10, 2023 | finance.yahoo.comLTRN: First Harmonic Patient DosedMay 9, 2023 | finance.yahoo.comLantern Pharma Reports First Quarter 2023 Financial Results and Operational HighlightsMay 3, 2023 | finanznachrichten.deLantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical TrialMay 3, 2023 | finance.yahoo.comLantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical TrialSee More Headlines Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees22Year Founded2013Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+222.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.45% Return on Assets-25.06% Debt Debt-to-Equity RatioN/A Current Ratio16.92 Quick Ratio16.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book0.66Miscellaneous Outstanding Shares10,870,000Free Float10,117,000Market Cap$37.07 million OptionableNot Optionable Beta0.75 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Panna Sharma PH.D. (Age 52)Pres, CEO & Director Comp: $633.25kMr. David R. Margrave (Age 62)CFO & Sec. Comp: $394.36kDr. Kishor Gopaldas Bhatia Ph.D. (Age 68)Chief Scientific Officer & Scientific Consultant Comp: $184.33kNicole LeberInvestor Relations Associate, Fin. & Admin. CoordinatorDr. Peter L. Nara D.V.M.M.S., Ph.D., Co-Founder & AdvisorMr. Ernest Kitt B.S.M.S, Head of Clinical OperationsMore ExecutivesKey CompetitorsViracta TherapeuticsNASDAQ:VIRXMarker TherapeuticsNASDAQ:MRKRCoya TherapeuticsNASDAQ:COYASocietal CDMONASDAQ:SCTLCytoMed TherapeuticsNASDAQ:GDTCView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 200 shares on 8/15/2023Ownership: 0.000%Geode Capital Management LLCBought 32,252 shares on 8/11/2023Ownership: 0.829%Renaissance Technologies LLCBought 20,300 shares on 8/11/2023Ownership: 0.413%Carlson Capital L PSold 29,900 shares on 8/10/2023Ownership: 0.875%CM Management LLCBought 15,000 shares on 8/4/2023Ownership: 0.691%View All Insider TransactionsView All Institutional Transactions LTRN Stock - Frequently Asked Questions Should I buy or sell Lantern Pharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LTRN shares. View LTRN analyst ratings or view top-rated stocks. What is Lantern Pharma's stock price forecast for 2023? 2 brokers have issued 1-year price targets for Lantern Pharma's stock. Their LTRN share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price. View analysts price targets for LTRN or view top-rated stocks among Wall Street analysts. How have LTRN shares performed in 2023? Lantern Pharma's stock was trading at $6.04 at the start of the year. Since then, LTRN stock has decreased by 43.5% and is now trading at $3.41. View the best growth stocks for 2023 here. When is Lantern Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our LTRN earnings forecast. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. What ETFs hold Lantern Pharma's stock? ETFs with the largest weight of Lantern Pharma (NASDAQ:LTRN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK). When did Lantern Pharma IPO? (LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. What is Lantern Pharma's stock symbol? Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN." How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantern Pharma's stock price today? One share of LTRN stock can currently be purchased for approximately $3.41. How much money does Lantern Pharma make? Lantern Pharma (NASDAQ:LTRN) has a market capitalization of $37.07 million. The company earns $-14,260,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. How can I contact Lantern Pharma? Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The official website for the company is www.lanternpharma.com. The company can be reached via phone at 972-277-1136 or via email at info@lanternpharma.com. This page (NASDAQ:LTRN) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.